Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791390 | 1.00 | KMT2A (0.55) | KMT2AMEN1MAPTNPC1LMNA | |
| SCHEMBL16835913 | 0.81 | KDM4E (0.46) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988138 | 0.81 | NPBWR1 (0.47) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988372 | 0.81 | CCR6 (0.48) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988817 | 0.81 | LMNA (0.49) | KMT2AMEN1MAPTNPC1LMNA | |
| SCHEMBL14988392 | 0.81 | KMT2A (0.58) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988521 | 0.80 | ALDH1A1 (0.43) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988595 | 0.79 | KMT2A (0.46) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL3156019 | 0.78 | MAPT (0.52) | KMT2AMEN1MAPTLMNATDP1 | |
| SCHEMBL14988622 | 0.78 | KMT2A (0.51) | KMT2AMEN1MAPTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2097382-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | KMT2A 1172/4885MEN1 368/4885MAPT 4523/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KMT2A 1951/4885MEN1 186/4885MAPT 4795/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | KMT2A 1951/4885MEN1 186/4885MAPT 4795/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | KMT2A 3292/4885MEN1 1094/4885MAPT 4671/4885 |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | CRBN, CDR2, POU2F2 | KMT2A 2086/4885MEN1 59/4885MAPT 4743/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KMT2A 1951/4885MEN1 186/4885MAPT 4795/4885 |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | KMT2A 1573/4885MEN1 3768/4885MAPT 4836/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | KMT2A 1755/4885MEN1 104/4885MAPT 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.